LonapaleneAlternative Names: RS 43179
Latest Information Update: 07 Apr 1999
Price : $50
At a glance
- Originator Roche Palo Alto LLC
- Class Antiparasitics; Antipsoriatics; Naphthalenes; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 24 Nov 1995 Discontinued-II for Psoriasis in Finland (Topical)
- 24 Nov 1995 Discontinued-III for Psoriasis in United Kingdom (Topical)